Quality Documentation 99%+ purity HPLC and Mass Spectrometry verified GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg per vial Batch-specific COA included with every order USA tested and fulfilled Read the GHK-Cu research overview Read the BPC-157 and TB-500 research overview For laboratory research purposes only
About the Author: Summer Kessel, RD, CSOWM, LDN, is a registered dietitian who specializes in nutrition and behavior change coaching for people on GLP-1 medications
At Southern Care Anesthetics, we do not recommend or prescribe BPC-157, as its use falls outside current regulatory guidelines and established standards of care in anesthesiology and pain management
These side effects usually go away fairly quickly
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
Our skilled team tailors each IV Hydration treatment to your specific needs, ensuring you receive the perfect balance of vitamins and nutrients for maximum results
